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ABSTRACT
A case of Stevens-Johnson syndrome (SJS) following treatment with sodium valproate is presented. A 55-year-old male suffering from
manic episode was treated with sodium valproate in addition to haloperidol and trihexiphenidyl. After two weeks he developed
cutaneous manifestations of SJS. He was treated with systemic steroids, antihistamines and topical calamine lotion and recovered after
a few weeks.
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Introduction
Sodium valproate was initially introduced as an anti epileptic
agent in1967, but over the years it has been used to treat a
variety of psychiatric disorders. The milder and commonly
occurring adverse effects of valproate are nausea, weight
gain, hyperammonaemia, menstrual disturbances, tremor,
hair loss, lethargy, sedation, behaviour changes, ataxia,
dysarthria, incoordination, flushing, and reversible
thrombocytopenia (Butler et al, 1999).
Stevens-Johnson syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN) are rarely reported side effects valproate
(Platin et al, 1995; Tsai & Chen, 1998; Poon & Ho, 2001 &
Mishra et al, 2002). Rzany et al (1999), in a case-control
study on the risk of SJS and TEN with various antiepileptic
agents reported the univariate relative risk as 120 for
carbamazepine, 91 for phenytoin, 57 for phenobarbital, 25
for lamotrigine, and 24 for valproate within the first 8 weeks
of therapy. The association of SJS with valproate was
confounded by concomitant short-term therapy with other
causal drugs in many studies. Roujeau et al (1995)
conducted a case control study  to quantify the risks
associated with the use of specific drugs. Drug use before
the onset of disease was compared in 245 people who were
hospitalized because of TEN or SJS and 1147 patients
hospitalized for other reasons. The crude relative risk for
SJS or TEN was as follows: carbamazepine, 90; phenytoin,
53; phenobarbital, 45 and valproic acid, 25. Poon and Ho
(2001) have reported SJS in a 52-year-old man with
inoperable anaplastic astrocytoma of left basal ganglion and
neuropathic pain two days after the commencement of
sodium valproate.
The disease may occur as a primary skin disorder or as a
skin manifestation of systemic infections, malignant or
chronic disease of internal organs or as a reaction to various
drugs (Breathnach, 1992). The principal sign of SJS is a
symmetrical distribution of grouped or isolated crops of
violaceous papules, macules or nodules of size 0.5 to 1 cm
with dome shaped surface. The lesions enlarge and become
purplish. There may be vesicles, bullae, pustules, urticarial
lesions and hemorrhagic sites. A rather characteristic lesion
is erythema iris, also described as “bull’s eye” or “target
lesion”. These are concentric erythematous rings with
central clearing. The lesions may be present anywhere on
the body but extensor surfaces are commonly involved.
Mucous membrane ulceration is also a common finding
(Breathnach, 1992). We report a case of SJS induced by
sodium valproate in bipolar affective disorder because of
its rarity.
Case report
Mr. R, a 55-year-old male was presented with one week
history of sudden onset of mental illness, characterised by
excessive talk, grandiose ideas of ability, restlessness,
excessive happiness and reduced need for the sleep. After
a thorough evaluation, diagnosis of manic episode was
made. He had a past brief episode of mania 20 years back
subsiding spontaneously. All investigations including
complete haemogram and blood biochemistry were within
normal limits. As an out patient, he was started on sodium
valproate 600 milligram per day, haloperidol 10 milligram
per day and trihexiphenidyl 4 milligram per day. Prior to
our treatment he was not receiving any medications. On
the 7th day after starting the therapy, he developed fever,
headache and myalgia. Within 24 hours, he developed
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widespread erythematous rashes. There were multiple
target lesions involving the trunk and limbs with blister
formation that lacerated easily. There was mucosal
involvement with hemorrhagic areas on the oral mucosa,
conjunctiva, and external genitalia. Sodium valproate was
discontinued on 8th day after seeing the skin reaction,
however haloperidol with trihexyphenidyl was allowed to
continue, as he was psychiatrically symptomatic. The skin
reaction was treated with oral prednisolone (60 mg/day in
tapering dosage), oral antihistamine (cetrizine 20 mg/day)
and topical calamine lotion. Within a week, severe ulceration
of oral mucosa was seen. Hemorrhagic crusting and grayish
white membrane were visible on the lips, palms and sole.
The skin lesions showed typical “target lesions” with
nercotized red area and grayish red swollen margins spread
all over the body. After 4 weeks, the mucosal and skin
lesions started subsiding; the eyes were the first to clear
and no sequelae was evident. By continuing haloperidol
and trihexiphenidyl in tapering dosage he became euthymic
within 4 weeks.
Discussion
SJS is a severe and extensive type of erythema multiforme
characterised by a severe necrotising cutaneous reaction
and involvement of several mucosal sites (oral, conjuctival,
and anogenital).  Late complications include pigmentation,
scarring, and skin contracture. The mortality rate of SJS is
5% to 15%.
Treatment of SJS should be individually tailored according
to the cause and complications of the syndrome. The most
severe cases should be considered for the intensive
treatment in a burns unit. Systemic corticosteroids should
not be used routinely, but may be justified in the early stages
of drug induced SJS.  Treatment should also focus on early
detection and prevention of common fatal complications
such as infection. Prophylactic antibiotic therapy should be
started before signs of infection manifest. Topical treatment
may include hydrocolloid or gauze dressings. The clinical
condition may require 3 to 6 weeks to resolve, depending
upon the extent and severity of the lesions. Alternative
systemic treatments are still experimental and include
haemodialysis, plasmapheresis, and cyclosporin therapy
(Poon & Ho, 2001).
After millions of prescriptions of sodium valproate, mostly
as an anti epileptic and recently as antimanic, there are
only a few reported cases of SJS due to this drug (Platin et
al, 1995; Tsai & Chen, 1998; Rzany et al, 1999 & Mishra et
al, 2002).   In the index case, the diagnosis of SJS was
consistent with the clinical description given in standard
dermatology textbooks. The algorithms for the implication
of a drug in causing an adverse skin reaction is as follows-
a) alternative causes, especially infections should be
excluded; b) the interval between the introduction of a drug
and the onset of reaction should be examined (for drug-
induced SJS it is 1-3 weeks); c) any improvement after
drug withdrawal should be noted; d) the physician should
determine whether similar reactions have been associated
with the same compound; e) any reaction with
readministration of the compound should be noted (Roujeau
& Stern, 1994).
In the absence of any systemic or local infection or exposure
to any other drug except haloperidol and trihexyphenidyl
(SJS is highly uncommon with these two drugs), the onset
of SJS within the second week of starting treatment and
with the fact that condition was improved with the
discontinuation of sodium valproate, suggests that the
condition was perhaps caused by sodium valproate. The
occurrence of life threatening side effects like one described
above, whatever be its frequency, is a reminder that sodium
valproate treatment carries a potential risk.
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